Robert Bell

Chief Scientific Officer

United States

Research Interests

Explore related searches

Professors in United States Professors in Drug Delivery Drug Delivery professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Robert Bell is the Chief Scientific Officer at Ascidian Therapeutics, based in the United States. His research focuses on gene therapy, particularly related to galactose metabolism and drug delivery across the blood-brain barrier. He has published several articles examining the efficacy of AAV-mediated therapies and the implications of genetic polymorphisms in neurological disorders.

Articles (6)

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Paul Gamlin

Professor

University of Alabama, Tuscaloosa

UNITED STATES

View details

Patricio O'Donnell

Head of Translational Medicine

Alto Neuroscience (United States)

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robert Bell

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

AAV-mediated expression of galactose-1-phosphate uridyltransferase corrects defects of galactose metabolism in classic galactosemia patient fibroblasts.

Considerations When Developing Blood-Brain Barrier Crossing Drug Delivery Technology.

A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system.

Assessment of galactose-1-phosphate uridyltransferase activity in cells and tissues.

Strategies for delivering therapeutics across the blood-brain barrier.

Schizophrenia-associated SLC39A8 polymorphism is a loss-of-function allele altering glutamate receptor and innate immune signaling.

Collaborators (2)

Paul Gamlin

Patricio O'Donnell

Make your next move.